Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, JoshuaD, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S,Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ,Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA;International Myeloma Working Group., Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma., «LEUKEMIA», 2008, 22, pp. 414 - 423 [articolo]
Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G.; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M., Proteasome inhibitors: Bortezomib in multiple myeloma, «HEMATOLOGY MEETING REPORTS», 2008, 2, pp. 127 - 132 [articolo]
SanMiguel J; Facon T; Cavo M., Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice., «CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY», 2008, 6, pp. s4 - s10 [articolo]
CAVO M; ATTAL M; GERTZ MA; GIRALT S; LUDWIG H; MORGAN GJ; ANDERSON KC., The current landscape of multiple myeloma treatment, «LEUKEMIA RESEARCH», 2008, 32, pp. S1 - S2 [articolo]
Hussein M.A.;Vrionis F.D.;Allison R.;Berenson J.;Berven S.;Erdem E.;Giralt S.;Jagannath S.;Kyle R.A.;LeGrand S.;Pflugmacher R.;Raje N.;Rajkumar S.V.;Randall R.L.;Roodman D.;Siegel D.;Vescio R.;Zonder J.;Durie B.G.;International Myeloma Working Group [..; Cavo M; ..], The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement., «LEUKEMIA», 2008, 22, pp. 1479 - 1484 [articolo]
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S., 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone., «IN VIVO», 2008, 22, pp. 513 - 517 [articolo]
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma., «HAEMATOLOGICA», 2007, 92(1), pp. 50 - 55 [articolo]
Cavo M, Current status of bortezomib in the treatment of multiple myeloma., «CURRENT HEMATOLOGIC MALIGNANCY REPORTS», 2007, 2, pp. 128 - 137 [articolo]
C. Terragna; M. Renzulli; D. Remondini; E. Tagliafico; E. Roncaglia; P. Tosi; E. Zamagni; P. Tacchetti; G. Perrone; M. Ceccolini; G. Martinelli; M. Baccarani; M. Cavo, Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM, in: , «BLOOD», 2007, 108(atti di: 48th American Society for Hematology Annual Meeting, Orlando, Florida, December 9-12, 2006) [atti di convegno-abstract]
Cavo M., Le gammapatie monoclonali., in: TURA S., Corso di Malattie del Sangue e degli Organi Emolinfopoietici., BOLOGNA, Esculapio, 2007, pp. 262 - 287 [capitolo di libro]
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA., Neuropathy in multiple myeloma treated with thalidomide: a prospective study., «NEUROLOGY», 2007, 69, pp. 573 - 581 [articolo]
Cavo M., Nonmyeloablative allotransplantation for myeloma: light and shade., «BLOOD», 2007, 109, pp. 3134 - 3135 [articolo]
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM., Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides., «BRITISH JOURNAL OF HAEMATOLOGY», 2007, 139, pp. 415 - 424 [articolo]
Terragna, C.; Renzulli, M.; Remondini, D.; Tagliafico, E.; Roncaglia, E.; Tosi, P.; Zamagni, E.; Tacchetti, P.; Perrone, G.; Ceccolini, M.; Brioli, Am.; Martinelli, G.; Baccarani, M.; Cavo, M., Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep), in: Haematologica, Vienna, Austria, 2007, 92(s2), pp. 92 - 92 (atti di: 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007) [atti di convegno-abstract]
Terragna C.; Renzulli M.; Remondini D.; Tagliafico E.; Roncaglia E.; Tosi P.; Zamagni E.; Tacchetti P.; Perrone G.; Ceccolini M.; Brioli AM.; Martinelli G.; Baccarani M.; Cavo M., Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep), in: , «HAEMATOLOGICA», 2007, 92(s2)(atti di: 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007) [atti di convegno-abstract]
